We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

47 hedge funds and large institutions have $9.28M invested in GT Biopharma in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,800% more call options, than puts

Call options by funds: $78K | Put options by funds: $2K

0.15% less ownership

Funds ownership: 0.49% → 0.34% (-0.15%)

18% less funds holding

Funds holding: 57 → 47 (-10)

28% less capital invested

Capital invested by funds: $12.9M → $9.28M (-$3.6M)

45% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 20

67% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 12

Holders
47
Holders Change
-10
Holders Change %
-17.54%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
20
Closed
12
Calls
$78K
Puts
$2K
Net Calls
+$76K
Net Calls Change
+$55K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$617K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$351K
3
E
Ergoteles
New York
+$205K
4
AWS
Atria Wealth Solutions
New York
+$148K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$64.9K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.96M
2
State Street
State Street
Massachusetts
-$979K
3
Morgan Stanley
Morgan Stanley
New York
-$336K
4
Northern Trust
Northern Trust
Illinois
-$315K
5
Renaissance Technologies
Renaissance Technologies
New York
-$307K
Name Holding Trade Value Shares
Change 		Change in
Stake
BJL
26
Brighton Jones LLC
Washington
$35K +$1.74K +23 +6%
Commonwealth Equity Services
27
Commonwealth Equity Services
Massachusetts
$33K – – –
Goldman Sachs
28
Goldman Sachs
New York
$32K -$76 -1 -0.3%
Two Sigma Advisers
29
Two Sigma Advisers
New York
$30K -$21K -277 -45%
WG
30
Welch Group
Alabama
$30K – – –
Russell Investments Group
31
Russell Investments Group
United Kingdom
$21K -$9.55K -126 -34%
TRCT
32
Tower Research Capital (TRC)
New York
$11K +$1.14K +15 +14%
UBS Group
33
UBS Group
Switzerland
$9K -$3.26K -43 -29%
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$6K -$2.8K -37 -36%
Simplex Trading
35
Simplex Trading
Illinois
$5K -$9.55K -126 -66%
Rockefeller Capital Management
36
Rockefeller Capital Management
New York
$5K – – –
Osaic Holdings
37
Osaic Holdings
Arizona
$4K +$152 +2 +6%
Wells Fargo
38
Wells Fargo
California
$2K -$74.9K -988 -98%
TF
39
TimeScale Financial
Massachusetts
$2K – – –
Citigroup
40
Citigroup
New York
$1K -$1.14K -15 -71%
BBPWM
41
Blue Bell Private Wealth Management
Pennsylvania
$1K – – –
CS
42
Credit Suisse
Switzerland
$1K +$455 +6 New
APA
43
American Portfolios Advisors
New York
$42 – – –
N
44
Nuveen
North Carolina
– -$204K -2,362 Closed
Allspring Global Investments
45
Allspring Global Investments
North Carolina
– -$74K -859 Closed
State Board of Administration of Florida Retirement System
46
State Board of Administration of Florida Retirement System
Florida
– -$52K -607 Closed
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
– -$46K -536 Closed
AQR Capital Management
48
AQR Capital Management
Connecticut
– -$37K -429 Closed
Deutsche Bank
49
Deutsche Bank
Germany
– -$31K -361 Closed
AIG
50
American International Group
New York
– -$25K -294 Closed
1
2
3

GTBP Hedge Fund Activity: Q2 2022 in Review

47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2022, worth a combined $9.28M — down 28% from $12.9M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of GTBP and 4 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $617K. The largest seller was BlackRock, cutting an estimated $1.96M.

  • 47 institutional investors held GT Biopharma (GTBP) as of Q2 2022, down from 57 in Q1 2022.
  • Funds reported $9.28M of GT Biopharma stock for Q2 2022, down 28% quarter-over-quarter.
  • 4 funds opened new GT Biopharma positions in Q2 2022 and 12 closed out, a net change of -8 holders.
  • The largest GT Biopharma buyer in Q2 2022 was Millennium Management, an estimated $617K added.
  • The largest GT Biopharma seller in Q2 2022 was BlackRock, an estimated $1.96M sold.

Based on aggregated 13F filings for Q2 2022.